Hepatitis C News

A real-world analysis has shown that a test-and-treat approach coupled with treatment with Epclusa is feasible and results in high cure rates among incarcerated patients with hepatitis C.

The majority of countries with a high burden of hepatitis C-related deaths have made little progress toward achieving the WHO goal of an at least 10% reduction in hepatitis C-related mortality by 2020, according to research presented at The Liver Meeting Digital Experience.

In addition to preventing premature death, treatment of hepatitis C with direct-acting antiviral agents can be significantly cost-saving for many countries, researchers reported at the Liver Meeting Digital Experience.

Treatment of hepatitis C virus in high-risk people via methadone clinics showed high rates of sustained virologic response, according to a presentation at The Digital Liver Meeting Experience.

Patients who received all medication up front and only monitored via two phone calls over 12 weeks achieved 95% sustained virologic response, according to a presentation at The Digital Liver Meeting Experience.

New data indicate that circulating microRNAs may increased risk for hepatocellular carcinoma among patients with chronic hepatitis C-related cirrhosis and a sustained virologic response.

Despite diagnoses of hepatitis C virus and cirrhosis in mothers, many infants are not tested within guidelines for possible transmission, according to a presentation at The Digital Liver Meeting Experience.

Universal screening of all adults and improved treatment rates are needed to achieve WHO goals designed to eliminate hepatitis C as a public health threat by 2030, according to a study presented during the Liver Meeting Digital Experience.

In a model presented at The Liver Meeting Digital Experience, experts showed that at-risk populations could be positively impacted by incremental changes in hepatitis C screening and treatment strategies.

Using two methods of engagement – with methadone treatment or in a navigation setting – researchers at The Digital Liver Meeting Experience showed people who inject drugs can achieve viral response in hepatitis C virus.